Rating: Neutral (Avoid/Wait-and-See) | Target Price: RMB 44-54 | Current Price: RMB 57.19 (close on 2026-10-27) | Margin of Safety: -23.1% (base-case fair value floor of RMB 44 vs. current price) | Time Horizon: 6-12 months
Meta info: Total share capital 2.068 billion shares, market cap approx. RMB 118.28 billion; PE (TTM) approx. 62.8x, PB approx. 6.66x; IPO share lockup expiring on 2026-12-03 for approx. 383 million shares (tushare basis, 18.5% of total share capital, approx. 2.2x the current free float, corresponding to approx. RMB 21.9 billion in market value).
China Uranium is one of the few domestic companies with a natural uranium franchise license and the exclusive supplier of natural uranium for nuclear power to CNNC and Huaneng Group—its industry position and asset scarcity are virtually unique in the A-share market. Global nuclear capacity expansion and rigid constraints on uranium supply constitute a genuine long-term tailwind. However, the current price of RMB 57.19 already fully prices in this tailwind: reverse DCF shows the market cap implies an implied ~21% CAGR in net profit attributable to shareholders over the next ten years (sensitivity range ~17%-27%), while the company's actual 2023-2025 CAGR was 14.1%, and Q3 2026 single-quarter growth slowed to +3.79%. Base-case fair value is RMB 44-54; the current price represents a premium of ~16.7% to the base-case midpoint and ~11.4% to the probability-weighted fair value across three scenarios (~RMB 51.4)—no margin of safety. Combined with the float structure repricing from the December lockup expiration and the low probability of delivering consensus expectations that imply Q4 single-quarter net profit roughly doubling YoY, the current risk/reward is asymmetric. Score fundamentals and price separately: the company's quality is excellent, but the price is expensive. We recommend avoiding/waiting until the lockup expiration plays out and the 2026 annual report and uranium price readings confirm the outlook before reassessing entry.
Opportunity in one sentence: The industry tailwind and franchise barrier are genuine, but the frozen price of RMB 57.19 already implies a ~21% ten-year profit CAGR, and the 2026-12-03 lockup expiration will expand the float by ~2.2x. Over the next 12-18 months, wait first for the lockup expiration to settle and for validation of the 2026-12-31 long-term contract price reading. The current risk/reward is asymmetric—not yet an allocable opportunity (evidence grade B).
The three most important sources of change in the next 6-12 months:
Primary stock price drivers ranked: ① Uranium price path → direction of 2027 delivery price reset and impairment risk on the RMB 11.7 billion inventory (thresholds: long-term contract ≥USD 95 = delivered; spot below USD 80 = alert, USD 75 = warning, USD 65 = bear-market trigger); ② Speed of float structure repricing after expiration (no-sale commitment = pressure removed; sustained high turnover with grinding decline = premium unwind continues); ③ Self-produced volume delivery and earnings quality (2026 full-year attributable net profit < RMB 1.85 billion or gross margin below 18% = falsification signal).
Verifiable expectation gaps (verified market anchors: Eastmoney consensus as of 2026-10-28, n=3): Sell-side 2026E attributable net profit approx. RMB 2.34 billion (implying Q4 single-quarter RMB 899 million, ~+102% YoY, versus historical Q4 at 27-35% of full year), 2027E approx. RMB 3.66 billion, median target price RMB 93.5; our own estimate: 2026E RMB 1.88-2.00 billion, 2027E RMB 2.25-2.55 billion, 15%-38% below consensus. The expectation gap points downward: unless the December long-term contract reading is ≥USD 95 AND Guoyou No. 1 reaches capacity, creating a double catalyst, consensus faces downward revision risk. Note the sample is only 3 firms, all Buy-rated—the stability of such small-sample consensus is limited.
The franchise license plus nuclear power owner qualification constitute an extremely high entry barrier, and long-term contract binding with CNNC/Huaneng provides order certainty—this is the core of the company's moat. But its economic boundaries must be stated honestly: the license has not translated into pricing power. Long-term contract pricing prioritizes "government-set prices and government-guided prices"; overall gross margin declined from 26.79% in 2022 (natural uranium business basis) to 20.48% in 2024, only recovering in 2025-2026 with lagged pricing; mineral rights renewal and the franchise policy itself are policy variables. Falsification conditions: adjustments to franchise policy, failure of mineral rights renewal, or a significantly concessionary long-term contract pricing formula.
The demand-side math is clear: at ~175 tU/GW-year, China's natural uranium demand rises from ~10,900 tU in 2025 to ~19,000 tU in 2030. But two adjustments must be made upfront: first, the company is only the exclusive supplier to the CNNC + Huaneng systems; CGN's ~42 GW of demand is covered by its own self-supply system (CGN Uranium/CGN Mining + Kazatomprom offtake)—national incremental demand is not the company's addressable increment. Second, the media-reported target of "5,000 tonnes domestic + 7,000 tonnes overseas by 2030" could not be traced to an official document; and on the overseas side, Rössing produced ~3,184 tonnes U3O8 (~2,700 tU) in 2025, and Etango won't see first production until 2028—the reachability of the 7,000-tonne overseas figure is questionable. The company's capacity pipeline (Guoyou No. 1, Nalinggou and other fundraising projects, Rössing Phase IV life extension to 2036, Etango's 80,000 tU resource) is directionally certain, but negative self-produced revenue growth in 2026H1 signals delivery pace is not linear. Falsification conditions: <6 units approved annually, Guoyou No. 1 capacity delay, continued decline in self-produced revenue in the 2026 annual report, or Etango construction delay.
Putting the three layers of evidence together: current price at 62.8x TTM, ~61x our 2026E, ~46-53x our 2027E; consensus 2026E implies Q4 single-quarter profit of RMB 899 million (~+102% YoY), whereas Q4 historically represents only 27-35% of full year (three-year sample), and Q3 single-quarter growth has already fallen back to single digits—consensus delivery requires an extremely steep Q4, with downward revision risk greater than upward. Our base-case fair value is RMB 44-54 (2027E attributable net profit RMB 2.3-2.5 billion × 40-45x); the current price carries a 16.7% premium to the base-case midpoint, 11.4% to the probability-weighted fair value, and -23.1% to the base-case floor. The stock has retraced ~45% from its January 2026 high of RMB 104.87—valuation compression is underway—but the current level has not yet returned to a level consistent with the delivery path. Falsification conditions: Q4 single-quarter attributable net profit ≥ RMB 900 million, long-term contract price holding above USD 95 triggering sell-side upgrades, or post-expiration heavy-volume stabilization above RMB 60.
The OCF/attributable net profit sequence for 2023→2026 first nine months is 0.70→0.35→-1.56→0.08; profits have failed to convert to cash for multiple consecutive periods. Both sides must be fairly presented: the large 2025 outflow was mainly proactive low-price procurement and uranium stockpiling (a strategic action, not profit inflation); OCF in the first nine months of 2026 improved 103.6% YoY, and inventory is roughly flat versus the start of the year; the surge in receivables reflects counterparties such as CNNC—central SOE customers—and the company attributes it to uncollected amounts still within credit terms. But our trend judgment stands: inventory of RMB 11.719 billion (~34% of total assets, impairment provision ratio only 1.06%), receivables of RMB 4.726 billion, short-term borrowings +94%—the cash support for earnings remains weak, and a uranium price decline in 2027 would add inventory impairment risk. Falsification conditions: OCF > RMB 500 million for two consecutive reporting periods, receivables/inventory declining, or cash conversion ratio >0.6 in the 2026 annual report.
The lockup expiration is a calendar-certain event: 383 million shares on the tushare basis (Eastmoney shows 436 million shares; defer to the company's expiration warning announcement), ~2.2x the current float, ~RMB 21.9 billion in market value. For a recently listed stock with 62.8x PE and a small-float premium, a supply-side structural change is itself a valuation repricing trigger. But "expiration ≠ selling" must also be made clear: the 8 shareholders are mostly central SOE platforms and industry-related parties (including customer Huaneng Nuclear Power); as of 2026-10-29 there is no pre-disclosure of any planned sales, nor any historical record of share increases/decreases; a no-sale commitment or extended lockup would actually remove the pressure. The chairman's resignation is, per the company, normal rotation within the central SOE system with handover completed, but a leadership change 10 months after listing, combined with multiple executive changes this year, means strategic continuity carries observation costs until the new chairman is in place (expected within 1-2 quarters). Falsification conditions: major shareholders issuing no-sale commitments, post-expersion four-week turnover <3% with stable prices, or a new chairman quickly in place with clear production and return targets.
Cycle coordinates: spot peaked at USD 106-107 in early 2024 → USD 64 in March 2025 → USD 85-100 range in 2026, at ~the 61st percentile since 2000; the USD 96.5 long-term contract price is a nominal record high, but still roughly one-third below the 2007 inflation-adjusted peak. Structurally, the supply-demand gap persists (2025 production ~65,000 tU vs. demand of 68,900 tU), and new industry long-term contracts at fixed prices of USD 94-102/lb (CGN-system basis) are corroborating evidence of high-price lock-in. For the company, lagged pricing means 2027 delivery prices are largely locked at 2026's high average—short-term this is actually earnings protection. The real exposure lies in the 2028 delivery price reset and the RMB 11.7 billion inventory (if spot sustains below USD 75 as a warning, USD 65 triggers the bear-market path of impairment + repricing), while new supply such as Etango landing after 2028 is a long-term cap on the price center. Falsification conditions: 2026-12-31 long-term contract reading ≥USD 95 with spot holding above USD 85 (upside); spot below USD 75 for two consecutive quarters (downside).
| Metric | 2023 | 2024 | 2025 | 2026 First 9M | 2026Q3 Single Quarter |
|---|---|---|---|---|---|
| Revenue (RMB 100M) | 148.01 | 172.79 | 198.94 | 157.99 | 52.16 |
| Revenue YoY | +40.5%* | +16.8% | +15.1% | +14.8% | +23.8% |
| Attributable net profit (RMB 100M) | 12.62 | 14.58 | 16.45 | 14.39 | 4.51 |
| Attributable YoY | — | +15.6% | +12.8% | +19.9% | +3.8% |
| Non-GAAP attributable net profit (RMB 100M) | 12.87 | 13.67 | 16.20 | 14.20 | — |
| Gross margin (overall) | — | 16.0% | 19.8% | 20.3% | 19.2% |
| Net margin (attributable) | 8.5% | 8.4% | 8.3% | 9.1% | 8.7% |
| Operating cash flow (RMB 100M) | 8.86 | 5.06 | -25.65 | 1.15 | -2.34 |
| Free cash flow (RMB 100M) | — | -12.31 | -44.91 | -8.02 | — |
| Cash (period-end, RMB 100M) | — | 38.18 | 82.50 | 50.42 | 50.42 |
| Interest-bearing debt (period-end, RMB 100M) | — | — | 78.46 | 82.20 | 82.20 |
| Debt-to-asset ratio (period-end) | — | — | 43.0% | 44.3% | 44.3% |
Notes: *2023 YoY is based on prospectus 2022 revenue of RMB 10.535 billion; period-end 2025 cash includes RMB 4.44 billion of IPO proceeds; net interest-bearing debt at end-2026Q3 approx. RMB 3.18 billion (cash 50.42 - interest-bearing debt 82.20); net debt/EBITDA ~1.0x (2025 estimate basis: profit before tax + interest + D&A ~RMB 3.3 billion; company does not disclose EBITDA); FCF = OCF - capex (first 9M 2026 excludes RMB 2.211 billion Etango equity subscription); 2026Q3 single-quarter OCF is derived as first 9M minus H1.
Metric change explanations (YoY ≥ ±20% excerpts, all with company explanations): ① 2025 OCF -607%—company attributes to larger operating scale driving natural uranium procurement, inventory up ~RMB 3.658 billion from beginning of period (proactive stockpiling); ② 2025 purchased natural uranium revenue +46.12%—higher sales volume to CNN Power and rising selling prices; ③ 2025 international natural uranium trading revenue -32.87%—fewer trading opportunities; positioned for market influence rather than as a profit pillar; ④ 2025 finance costs +124%—higher interest expense and FX losses; ⑤ First 9M admin expenses +46.8%—supplementary exploration costs for the Rössing Z20 deposit; ⑥ Accounts receivable +134.8% from beginning of year—some Q3 sales still within credit terms and uncollected; ⑦ Cash -38.9% from beginning of year—payment of Etango equity subscription and loan repayments; ⑧ Short-term borrowings +94%, notes payable +3044%—adjustments to financing and notes settlement structure.
For the first three quarters of 2026, revenue was RMB 15.799 billion (+14.78%), net profit attributable to parent RMB 1.439 billion (+19.92%), and non-recurring-adjusted net profit RMB 1.420 billion (+18.54%) — on a cumulative basis, consistent with the path of "volume growth + mild, lagged price pass-through." However, on a quarterly basis, Q3 revenue was RMB 5.216 billion, up +23.81% YoY, while net profit attributable to parent was only RMB 451 million, up +3.79% YoY — clear revenue growth without profit growth. Quarterly gross margin fell to 19.2% (20.3% for the first three quarters overall), credit impairment losses were RMB 146 million (up +104.17% YoY, which the company attributed to increased provisioning on receivables within credit terms), and administrative expenses surged due to a sharp increase in Rössing Z20 exploration costs — these were the main drags. Marginal cash flow improvement is the most substantive positive signal this quarter: OCF for the first three quarters was +RMB 115 million (vs. -RMB 3.194 billion in the same period last year), and inventory rose only +0.38% from the start of the year, no longer accumulating. The balance sheet has tightened after Etango payments (cash down -38.9% from year-start): receivables of RMB 4.726 billion and short-term borrowings of RMB 3.733 billion.
Against expectations: sell-side consensus for 2026E net profit attributable to parent is about RMB 2.34 billion, implying Q4 alone needs RMB 899 million, roughly +102% YoY — historically Q4 accounts for 27-35% of the full year (34.7% in 2024Q4, 27.1% in 2025Q4); even extrapolating at the upper-bound 35% ratio, Q4 would be around RMB 750-800 million, making the consensus threshold very hard to hit. Our own estimate for the full year is RMB 1.88-2.00 billion (Q4 roughly RMB 450-560 million, +0%-25% YoY). Management gives no quantitative guidance; "Guoyou No. 1 reaching full production by end-2026" is the only timing anchor — first-year production ramp-up plus year-end concentrated settlement (including the customary impairment provisions) makes Q4 earnings highly volatile in both directions, the biggest uncertainty before the annual report.
Model in brief: A hybrid of asset-heavy mining plus trading. Domestic sandstone-type in-situ leaching uranium mining (exclusive franchise) + the Rössing open-pit mine in Namibia (68.62% controlling stake) + the Etango interest (42.75%) form the self-production base; purchased uranium resale (long-term contracts with Kazatomprom/Orano) and international trade serve supply security and strategic positioning; plus a second growth curve in radioactive co-/by-product comprehensive utilization (monazite/tantalum-niobium/uranium-molybdenum), about 9.6% of 2025 revenue. Revenue is highly recurring — dominated by long-term contracts: in 2025, self-produced + purchased uranium priced under long-term contracts accounted for about 73.6% of revenue, but pricing power is constrained by pricing formulas (government-set/guided prices take priority, with lagged market prices) — this is not a free-pricing model.
Cash content of earnings: OCF/net profit attributable ratio for 2023 through 2026 first three quarters: 0.70 → 0.35 → -1.56 → 0.08, long below the 0.8 warning line; FCF was -RMB 1.231 billion in 2024 and -RMB 4.491 billion in 2025. The 2025 figure was mainly due to deliberate uranium stockpiling (inventory +RMB 3.658 billion); the first three quarters of 2026 improved to +RMB 115 million but remain weak in absolute terms. Conclusion: the bulk of book profits are currently locked up in inventory and receivables; cash conversion needs validation in 2027 (price reset + receivables decline). The gap between non-recurring-adjusted and attributable profit is small (RMB 1.620 vs 1.645 billion in 2025, -1.5%), with no one-off gains window-dressing; in fact, 2025 non-recurring items included an impairment of long-term assets at the Xincun uranium mining and metallurgy project (-RMB 309 million item).
Return on capital: 2025 ROIC was about 7.8% (about 10-11% excluding idle IPO cash), below the ~9.5% cost of equity/industry-boom level — high-price stockpiling plus capacity under construction that has yet to generate output diluted current returns; 2027-2028, after capacity is commissioned, will be the key checkpoint.
CapEx quality: CapEx/depreciation was 4.24x/3.70x in 2024/2025, consistent with an expansion phase (Nalinggou, Rössing Phase 4, monazite, Etango); maintenance capex is not separately disclosed and cannot be broken out — note the distinction: this is not a cash cow, but a phase of "burying cash underground in exchange for 2027-2030 output."
Moat and red flags: Moat = exclusive franchise + mineral rights reserves + system integration (see C1); red flags = customer concentration (top five 79.46%, related parties 57.52%) + thin-margin purchased volume growth (net margin falling from 14.4% in 2022 to 8-9%) + weak cash conversion. Overall judgment: fundamentally a strategic scarce-resource business, but reported earnings quality is mediocre; value realization lies in the years ahead.
Track record vs. words: partially delivered. ① Dividend commitment of "annual cash dividends of no less than 30% of distributable profit" — actual 2025 payout was RMB 538 million, a 32.68% payout ratio: delivered. ② 2025 annual report operating plan to "accelerate Etango closing and Rössing Phase 4 development" — Etango consideration fully paid and closing completed in September 2026; Rössing Phase 4 in progress: delivered (ongoing). ③ IPO prospectus project "CNNC Huazhong 1,000-ton tantalum-niobium capacity ramp-up and efficiency gains" — the company itself admits it "did not achieve projected benefits" (first-year ramp-up friction): not delivered (first year). Overall pragmatic; the absence of quantitative earnings guidance is honest (better none than unreliable).
Shareholder friendliness: neutral to friendly. Delivered the 30% payout ratio right after listing (frozen-market-cap dividend yield about 0.45%; the low absolute level reflects high valuation); no buybacks — asked three times on the investor platform about share increases/buybacks, the company only replied "if there is a plan, it will be disclosed per regulations," making no commitment; IPO issued 248 million shares (12% post-issue) as a one-time dilution, with no refinancing record.
Risk signals: Chairman Yuan Xu resigned on 2026-09-30 (tenure under 6 months; company cites work reassignment; holds no shares); multiple other executive changes within the year, including employee director and chief legal counsel; 2026 related-party transaction quota raised to RMB 27.712 billion (RMB 15.751 billion already incurred in H1) — deep group procurement/sales integration is a double-edged sword: order visibility coexists with related-party pricing fairness that is hard to verify externally. No controlling-shareholder selldown, no compliance violations.
| Segment | 2025 revenue share | Gross margin (2025) | YoY | Business logic in one line |
|---|---|---|---|---|
| Self-produced natural uranium (domestic ISL + Rössing) | 20.57% | 43.94% (down to 38.15% in 2026H1) | +0.94% | Franchise + mineral rights control, core profit source |
| Purchased natural uranium products | 53.05% (up to 61.08% in 2026H1) | 15.46% (18.78% in 2026H1) | +46.12% | Long-term contract purchase-resale for supply security, earning spread timing gains |
| International natural uranium trading | 15.59% (down to 9.43% in 2026H1) | 1.39% (0.51% in 2026H1) | -32.87% | Overseas spot trading; strategic positioning, not profit |
| Radioactive co-/by-product utilization | 9.55% (10.93% in 2026H1) | Not separately disclosed | Rare earth chloride +78% | Monazite/tantalum-niobium/uranium-molybdenum recovery, second curve |
Profit drivers: Estimating gross profit contribution via "revenue share × gross margin" — self-produced natural uranium gross profit about RMB 1.80 billion in 2025 (revenue RMB 4.092 billion × 43.94%); purchased about RMB 1.63 billion (RMB 10.554 billion × 15.46%); trading about RMB 40 million; co-/by-products about RMB 200 million (estimated basis). The largest-revenue purchased segment and the self-produced segment now contribute gross profit in nearly a 1:1 ratio, while self-production is only 20% of revenue — profit quality depends on self-produced volume growth, not revenue scale. The gross margin structure gap (43.94% vs 1.39%) spans 42.5 percentage points: one is a resource + license business, the other a channel business; they must not be conflated. The trend is notable: purchased share is still rising (61.08% in 2026H1), and the revenue mix is drifting toward lower margins until new self-produced capacity takes over.
Accounting red flags: ① Highly concentrated related-party sales with rapidly rising quotas (severity: medium) — CNNC Group accounts for 57.52%; the 2026 estimated quota is RMB 27.712 billion; independent directors raised no objection, but pricing includes lagged fixed prices and fairness is hard to verify externally; ② Receivables up +134.8% from year-start, far outpacing revenue growth (+14.8%) (medium) — counterparties are SOE customers and the company says they are within credit terms, but the lengthening trend warrants tracking; ③ Inventory of RMB 11.799 billion with a write-down provision rate of only 1.06% (medium) — listed as a key audit matter; a concentrated impairment exposure exists in a falling uranium price scenario (NRV ≥ cost is normal in an upcycle; the risk is conditional); ④ Provision for liabilities on fixed-price sales spread inversions (medium) — fixed-price contracts signed in 2023, hit by the uranium price surge, with unexecuted portions still loss-making; ⑤ Decommissioning and mine-closure/rehabilitation provisions reliant on long-cycle estimates (low) — domestic provisions accrue a 20% terminal value on fixed-asset original cost; Rössing mine-closure/rehabilitation provision is RMB 1.537 billion.
Cross-period consistency: ① Four-year OCF/attributable-profit series 0.70 → 0.35 → -1.56 → 0.08 — consistent with the company's explanation (deliberate stockpiling, credit terms), but the direction has not yet reversed; ② Persistent divergence between receivables growth and revenue growth (2025: +22.5% vs +15.1%; a spike to +173.7% at one point in 2026) — company explains "within credit terms"; consistent but needs verification; ③ Purchased + trading revenue share vs. net margin center — net margin fell from 14.4% in 2022 to 8-9%; the revenue mix drift and profitability decline corroborate each other, in tension with the prospectus positioning that "purchases supplement and secure supply" (the supplementary channel has become the main revenue source). On disclosure history: listed only 10 months, but the prospectus provides audited 2022-2024 data, so cross-period assessability is adequate. Overall judgment: no systematic accounting-craftsmanship traces; the core concerns are the fairness of related-party pricing and the conditional risks in two balance-sheet items — inventory and receivables.
Reserves and production table (as disclosed as of 2025-12-31):
| Mine/project | Ownership | Resources/reserves | 2025 output | Mine life | Notes |
|---|---|---|---|---|---|
| Rössing Uranium Mine (Namibia) | 68.62% controlling | Overseas combined uranium metal in reserves ~225,300 tonnes (implied grade ~0.023%) | 3,184 t U3O8 (+22.5%, ~2,700 tU), capacity 4,500 t/yr, utilization ~71% | Phase 4 life extension to 2036 (total investment ~RMB 1.13 billion) | Output 2022-2025: 2,659 → 2,920 → 2,600 → 3,184 t; Z20 zone under exploration |
| Etango (Namibia) | Indirect 42.75% | JORC measured + indicated + inferred 80,000 tU (~34,200 tU attributable) | — (first production target 2028) | Pre-production | Consideration ≤ USD 322 million fully paid; 60% of lifecycle product offtake rights |
| Domestic mines (Tianshan/Inner Mongolia/Jinyuan, etc.) | 100% | Output/reserves disclosure-exempt | Not disclosed | — | 19 mining licenses + 6 exploration licenses; Guoyou No. 1 full-production guidance by end-2026; Nalinggou progress 72.33%, Bayan Wula Phase 2 89.53% |
| Equity stakes | LH 25%, SOMINA 37.2% | — | — | — | Niger SOMINA equity pledged as collateral for RMB 613 million guarantee |
Reserve replacement rate not disclosed (domestic data exempt; no unified basis) — this is a structural blind spot in the company's resource disclosure; overseas reserve reporting is clear, while domestic reserves can only be observed indirectly.
Unit economics: The company does not disclose per-tonne cash cost/full cost; observable proxies — self-produced segment gross margin 43.94% in 2025 (38.15% in 2026H1); the prospectus states unit costs fluctuate little, mainly affected by sulfuric acid prices and Rössing maintenance. Global comparison: Kazatomprom C1 cash cost USD 24.48/lb (2026H1, +37% YoY); Cameco blended cash cost ~USD 39/lb. Based on ISL (CO2+O2) and heap-leach processes and the gross margin level, the company sits in the lower-middle of the global cost curve (roughly the 15%-35th percentile, inferred) — clearly above Kazakhstan pure-ISL, below Western restart mines.
Hedging and price sensitivity: No uranium price derivative hedging whatsoever (2026 semi-annual report: "no derivative investments"); risk buffering relies entirely on long-term contract price adjustment mechanisms (ex-post negotiation, non-binding). Price structure: sales dominated by long-term contracts (in 2025, self-produced + purchased long-term-contract pricing = 73.6% of revenue); pricing = fixed price + prior-year average price (lagged ~12 months); procurement references a 1-9 month average price. Sensitivity is not quantified/disclosed. Structural characteristics: in a mild upcycle, gross margins expand but with a lag; in a sharp spike, purchased costs rise first and compress gross margins instead (20.48% in 2024 was the trough); in a downturn, price resets and inventory impairments transmit in sequence in 2027-2028. FX exposure: USD/NAD/EUR assets; FX translation difference -RMB 78 million for the first three quarters.
Geopolitics and mining rights: Namibia (Rössing + Etango; non-diamond mining income tax 37.5%; antitrust and other approvals completed); Niger (SOMINA 37.2%, high-risk Sahel zone — the country already has a 2025-2026 precedent of a junta taking over Orano's uranium mines and reassigning them to state entities; the company's guarantee exposure is RMB 613 million); Kazakhstan (long-term purchases from Kazatomprom; Russian sulfuric acid export ban threatens its output); Mongolia (minimal exposure). Single-country concentration (Namibia) rises further after the Etango closing.
NAV perspective: Sum-of-the-parts — domestic self-production franchise (gross-margin back-calculation + growth discounted to 2036) ~RMB 17.9 billion; Rössing DCF (attributable RMB 245 million × 11 years, 10.5% discount, zero terminal value) ~RMB 1.55 billion; Etango (cost floor RMB 2.15 billion + development option) ~RMB 2.4 billion; purchased + trading segments ~RMB 3.2 billion; co-/by-products ~RMB 2.6 billion; net debt -RMB 2.82 billion — NAV ~RMB 24.8 billion, ~RMB 12.3/share (range RMB 11-14). The current price of RMB 57.19 is roughly 4.7x NAV. Input gaps must be stated honestly: domestic output is disclosure-exempt so only gross-margin back-calculation is possible; Etango capex and production details are undisclosed; purchased/co-/by-product segment net profit is on an estimated basis — NAV is a floor reference, not fair value.
Current market data (2026-10-27 close): Price RMB 57.19, market cap RMB 118.28 billion, PB 6.66x (Q3 attributable net assets RMB 17.763 billion), PE(TTM) 62.8x. PE/PB percentile since listing ~4%/5% — but the listing is only 10.5 months old and the starting point was the post-listing speculative peak (interval PE median 83.8x); percentile is reference only, not a cheapness/expensiveness signal. Peer benchmarks:
| Company | PE(TTM) | PB | Key points |
|---|---|---|---|
| China Uranium | 62.8 | 6.66 | 2026E consensus ~50.6x / own estimate ~61x; 2027E consensus 32.3x / own 46-53x |
| Kazatomprom | ~13.1 | ~3.9 | Lowest-cost producer globally + ~21% primary supply share, high dividends; cyclical low-multiple anchor |
| Cameco | ~84 (GAAP-distorted) | — | Westinghouse consolidation amortization depresses book profit; 2027E consensus ~57x; Huatai/AVIC price targets both anchor here |
| CGN Mining (1164.HK) | 37.8 | 3.71 | Trading-type, volatile earnings; HK uranium resource anchor |
| A-share nonferrous mining median | 19.8 | — | This stock trades at 3.2x that level |
Market-implied expectations: Reverse DCF (base case 2026E attributable profit ~RMB 1.94 billion, discount rate 9.5%, ten-year explicit + 3% perpetuity) shows the RMB 118.28 billion market cap implies a ~21% CAGR in attributable profit over the next decade — corresponding to ~RMB 2.8 billion in 2028, ~RMB 4.2 billion in 2030, ~RMB 13 billion in 2036 (equivalent to recreating about 8x the 2025 earnings base); sensitivity across 9.5%-12% discount rates and 15-30x exit multiples spans 17%-27%. In one sentence, "what the current price demands of the company": a decade of ~20% compound growth, while reality is 14.1% over the past three years and +3.8% in the latest quarter — the implied growth only holds if all three conditions of "uranium price center moving above USD 110 + all kiloton-scale bases reaching full production + Etango starting on schedule" are met; the current price implies roughly a 36% probability of that combination, which this report assesses at ~20%.
Three-layer value (EPV): Asset value ~RMB 8.59/share (book BVPS; resource-basis NAV of RMB 12.3/share as an independent reference); EPV (zero growth, equity basis: normalized FCFE RMB 0.94/share ÷ 9.5% cost of equity) ~RMB 9.89/share (range 8.9-11.5); growth/cyclical option layer ~RMB 47.3/share, about 83% of the current price. A high growth-option share does not by itself constitute an overvaluation conclusion — volume growth has industrial logic (Guoyou No. 1, IPO projects, Rössing, Etango); the final cheapness/expensiveness verdict depends on the gap between implied growth and actual delivery — the math in the previous paragraph.
Three scenarios and odds (probabilities assigned by this report):
| Scenario | Probability | Fair value range | vs. current price | Swing factor |
|---|---|---|---|---|
| Bear | 30% | RMB 25-32 | -56.3%~-44.0% | Spot falls back to the USD 64 level + post-lockup-expiry liquidity premium clearance: 2027E attributable profit RMB 1.7-1.9 billion × 30-35x |
| Base | 50% | RMB 44-54 | -23.1%~-5.6% | Uranium price oscillating at USD 85-95 + Guoyou No. 1 ramping up, mild volume-price delivery: 2027E attributable profit RMB 2.3-2.5 billion × 40-45x |
| Bull | 20% | RMB 83-100 | +45.1%~+74.9% | Long-term contract re-signing breaking USD 110 + full production + Etango early: 2028E attributable profit RMB 3.8-4.2 billion × 45-50x |
Probability-weighted fair value ~RMB 51.4, expected return ~-10.2%; the current price sits above the base-case range's upper bound and below the bull range — odds are downward-skewed but both tails are fat (bear -44%~-56% vs. bull +45%~+75%). Rationale for anchoring the base-case exit multiple at 40-45x: a ~20%-30% discount to Cameco's 2027E consensus ~57x (the common anchor of both sell-side price targets; delivery-certainty and liquidity discount), a premium to Kazatomprom's 9.7-13.1x (A-share SOE scarcity + franchise certainty + growth duration), a premium to the A-share nonferrous median of 19.8x (scarcity of a strategic nuclear-fuel asset) — not anchored to this stock's current multiple; the current price corresponds to ~46-53x our own 2027E estimate, shown for comparison.
Own earnings forecast (reconciliation anchor): 2026E revenue RMB 21.8-22.6 billion, attributable profit RMB 1.88-2.00 billion (Q4 ~RMB 450-560 million); 2027E revenue RMB 24.3-26.2 billion, attributable profit RMB 2.25-2.55 billion. Three-way comparison: management gives no quantitative guidance (Guoyou No. 1 full production by end-2026 + payout ratio ≥30%); sell-side consensus 2026E RMB 2.34 billion / 2027E RMB 3.66 billion (n=3, all Buy); this report is 15%-38% below consensus — the divergence centers on Q4 delivery concentration and the slope of 2027 price pass-through.
Conclusion: Overvalued. Target price RMB 44-54 (= base-case fair value), margin of safety -23.1% (base-case fair-value floor vs. current price). Quality and price assessed separately: a good company, but the current price is not a good price.
Industry Size: Natural uranium sits at the very top of the nuclear fuel chain. Per WNA's World Nuclear Fuel Report 2025: global reactor uranium demand will be 68,920 tU in 2025, with the reference scenario reaching approximately 89,000 tU by 2030 and over 150,000 tU by 2040 — an implied CAGR of about 5.3% (upper scenario: 204,000 tU). This is one of the rare energy commodities globally exhibiting a "demand curve steadily shifting rightward." In monetary terms: at a spot price of roughly $90/lb, the primary market is worth about $16.1 billion annually (the full front-end market including conversion, enrichment, and fabrication is on the order of $40 billion). Historical growth: global demand CAGR of about 2.5% from 2021–2025; 2025 nuclear generation hit a record 2,702 TWh — growth is transitioning from "restocking-driven" to "capacity-driven." China specifics: 59–62 reactors in operation / ~62.5 GW in 2025, with natural uranium demand of about 10,900 tU; 58 reactors approved and under construction / 69.51 GW; the "15th Five-Year Plan" carbon peaking program anchors ~110 GW of operating capacity by 2030, and the China Nuclear Energy Association projects nuclear at about 10% of generation by 2035 — implying China's uranium demand at ~19,000 tU by 2030 (+76%), contributing roughly 40% of global incremental demand over the period.
Quantified Chain of the Demand Inflection: Driver variables = China nuclear capacity 62.5 GW (2025) → 110 GW (2030 target) + global 398 GWe (June 2025) → 746 GWe (2040 reference scenario); unit consumption is stable (~175 tU/GW·year, back-calculated from WNA demand ÷ operating capacity, no step-change per unit); penetration ramp = nuclear's share of generation climbing from 4.6% (2025) toward 10% (2035); company share = capturing incremental demand from the CNNC + Huaneng systems (national-level share must exclude CGN's ~42 GW of self-supply). Conclusion: this is policy/capacity-driven, certain demand expansion — not a single technology platform shift — a genuine tailwind for both uranium prices and company volume growth, but the slope materializes on a 5-year horizon (construction period of ~5 years for units under construction; first core loading equals 2–3x annual consumption; loading demand for units approved in 2026–2028 will be concentrated in 2028–2031).
Value Chain and Value Distribution: Uranium exploration, mining, and metallurgy (the Company) → conversion → enrichment → fabrication → nuclear power operations. Natural uranium accounts for only 1%–2% of nuclear generation costs — downstream players can absorb uranium price increases easily with little transmission friction — so elasticity in gross margin accrues mainly at the mining/metallurgy stage. Midstream conversion and enrichment are dominated domestically by the CNNC system (oligopoly with high margins), while global enrichment capacity is tight due to the Russia-Ukraine conflict. The Company has strong bargaining power downstream (domestic monopoly + exclusive supplier status), but its pricing formula is constrained by government-set/guidance prices and long-term contract formulas — qualification monopoly ≠ price monopoly; its bargaining power upstream (purchases from Kazatomprom/Orano, sulfuric acid and other reagents) is moderate — purchase prices reference a 1–9 month average while sales prices lag 12 months; this mismatched-timing structure is both a protection and a friction.
Supply-Demand and Competitive Landscape: 2025 global production of ~65,000 tU vs. demand of 68,900 tU — a gap of ~3,900 tU covered by secondary supply (inventories, underfeeding, HEU dilution) that is declining; 2026E supply growth of 3%–4% < demand growth of ~5.3%. Supply-side rigidity: a decade-long capex drought post-Fukushima (2011–2021), Kazakhstan's sulfuric acid bottleneck (Russian embargo; Kazatomprom C1 cost +37%, Budenovskoye ramp-up delayed), Kazakhstan's MET tax rate rising 9% → 12.4%, and new project lead times of 5+ years (NexGen, Etango, Boss) — the 2011–2021 shortfall cannot be made up in the short term. Concentration is extremely high: the top 10 producers account for ~92% of global output (2022, Kitco/WNA), CR5 ~60% — Kazatomprom (attributable 12,286 tU, ~21% of primary supply), Cameco (~9,000 tU), Orano (~5,500 tU), Uranium One/CGN system (~4–5% each) — figures are a 2022–2024 mixed sample, to be verified. Competitive behavior resembles oligopoly coordination rather than price wars: 2025 global long-term contract signings still fell short of actual demand (per Kazatomprom), with mines having "no spare capacity and some requiring buyers to bear capex." Entry barriers are extremely high (fivefold: mining rights/nuclear safety approvals/capital/technology/customer access); substitutes (secondary supply, thorium/fast reactors/fusion) pose no commercial substitution before 2035. China's domestic market is an exclusive franchise structure: only China Uranium and its subsidiaries/JVs may engage in domestic natural uranium mining and metallurgy — domestic share basis: the Company is one of the few franchise license holders and the exclusive supplier to the CNNC + Huaneng systems; CGN system demand flows through its own supply chain and is not covered by the Company (share statements follow this basis; the ~5% global attributable share is an estimate, to be verified).
Cycle and Regulation: The uranium price cycle template — $7 low in 2000 → $136 bubble peak in June 2007 → long bear market post-Fukushima → $18 trough in March 2020 → $106–107 peak in Jan/Feb 2024 → pullback to $64 in March 2025 → $85–100 range in 2026. Current position: spot at ~$90 sits at roughly the 61st percentile since 2000, about 15% below the 2024 peak; the long-term contract price of $96.5 is a nominal record high (in real terms, about one-third below the 2007 peak). Leading indicators: ① long-term contract prices and signing volumes (a 2030–2035 re-signing wave approaching); ② Kazatomprom production and costs (2026 guidance of 27,500–29,000 tU below capacity); ③ China's annual reactor approvals (2022–2026: 10/10/11/10/8 units); ④ US nuclear policy (May 2025 "nuclear renaissance" executive orders; January 2026 designation of natural uranium as a critical mineral) and AI giants' power purchase agreements (Google's 22-year Finnish nuclear deal, among others). Regulatory direction is broadly favorable: China's Atomic Energy Law takes effect January 1, 2026 (first national legislation for nuclear power development); the US ban on Russian uranium (waivers until end-2027) is reshaping a non-Russian supply chain premium. Risk side: Kazakhstan's reliance on Russian sulfuric acid is an inverse tail risk; Niger's political instability exemplifies resource-country risk.
Peer Comparison Table:
| Company | 2025 Revenue Scale | Growth | Gross Margin / Profitability | Output / Share | Key Differences vs. the Company |
|---|---|---|---|---|---|
| China Uranium | RMB 19.894 billion (~USD 2.78 billion, incl. 53% purchased-for-resale) | +15.1% | Overall gross margin 19.8%; self-produced 43.94% | Rössing ~2,700 tU + domestic (disclosure exempted); global top 10 | Domestic franchise + system lock-in; trading throughput inflates revenue |
| Kazatomprom | ~USD 3.4 billion | -0.6% (tenge) | Net margin ~32%; C1 $24.48/lb | Attributable 12,286 tU, ~21% | Lowest-cost resource-country national champion, high dividends |
| Cameco | ~USD 2.5 billion (CAD 3.5 billion) | Turned positive in 2025 | 2025 net profit attributable +243% (Westinghouse amortization depresses book) | 2026 own share 19.5–21.5M lbs | Mine + fuel + 49% Westinghouse integration; Western exposure |
| CGN Mining (1164.HK) | 2024 trading volume HKD 8.624 billion | Highly volatile (-58% in 2026H1, then recovery) | Trading-type gross margin ~0–1%; 2026H1 loss of HKD 70 million | Attributable 1,317 tU (2025) | Pure overseas equity + trading, no domestic mining rights |
Company's Industry Position: The undisputed domestic leader (franchise license + exclusive supply), a chaser among the global top ten — its attributable output and cost curve still lag Kazatomprom's left-end position significantly, with ~53% of revenue from purchased trading (gross margin 15.5%) diluting overall earnings quality. Share trend is upward (Guoyou No. 1, fundraising projects, Rössing Phase 4, and Etango rolling out sequentially, targeting ~12,000 tU supply capacity by 2030 — roughly 60% of China's demand). Moat sources: franchise license and mining rights reserves (dual policy + resource barriers), system lock-in (60-year fuel cycle long-term contracts), and CO2+O2 third-generation in-situ leaching technology. Note on market position basis: the Company's own claims align with industry association data (global top ten producer, WNA basis); the "100% domestic share" figure is a broker estimate — the Company's annual report states it is "one of the few domestic enterprises holding a natural uranium franchise license"; both bases coexist, with the latter taking precedence.
Overall Assessment: Neutral (avoid/wait-and-see), confidence 0.55, time horizon 6–12 months. China Uranium possesses a strategic nuclear fuel asset scarce in the A-share market amid genuine industry tailwinds, but 62.8x TTM already prices in a decade of ~20% compound growth, while the delivery path already shows Q3 deceleration, the December share unlock imminent, and consensus estimates at risk of downward revision — expected return of about -10% with fat tails; this is not a good entry point. Strategy: Avoid. Two re-evaluation triggers: ① price falling below the baseline fair-value floor of RMB 44 (implying self-tested 2027E P/E below ~39x, improving odds); ② fundamental disproof removed (Q4 quarterly net profit attributable ≥ RMB 900 million meeting consensus, or long-term contract price holding above $95 triggering an upward-revision cycle). If major shareholders commit not to sell around the December unlock, the overhang could be reassessed earlier.
Key Risk Warnings: Uranium price cycle downturn (spot sustained <$75 as warning, <$65 triggering a double hit of inventory impairment + repricing — note that lagged pricing means the double hit mainly transmits to 2028); post-unlock valuation compression (62.8x → 40x implies about -36%; → 30x implies about -52%; unlock size of 383 million/436 million shares subject to company announcements); earnings quality (receivables +135%, inventory RMB 11.7 billion, weak OCF); governance transition (chairman vacancy, related-party transaction quota RMB 27.7 billion); geopolitics (Niger guarantee of RMB 613 million, Namibia concentration, Kazakh sulfuric acid); FX (translation of USD assets, -RMB 78 million in the first three quarters).
Tracking Calendar and Verification Points: December 3, 2026 share unlock (shareholder no-sale commitments / pre-disclosure of sales / turnover rate); December 31, 2026 UxC long-term contract price reading (≥$95 = repricing delivered; <$85 = warning); February–April 2027 earnings flash report / annual report (full-year net profit attributable vs. self-tested RMB 1.88–2.0 billion, self-produced revenue breakdown, OCF, payout ratio); nuclear approval batches and new chairman election within 2027; Etango construction milestones (first production target 2028).
Data in this report as of October 29, 2026; price anchor is the October 27, 2026 closing price of RMB 57.19 (frozen basis); financial data from the Company's prospectus, 2025 annual report, 2026 Q1/interim/Q3 reports, and Juchao temporary announcements; industry data from WNA, UxC/Cameco, the National Energy Administration, the China Nuclear Energy Association, and other public sources. This report does not constitute investment advice.